Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) EBITDA Margin (2016 - 2025)

Haemonetics (HAE) has 17 years of EBITDA Margin data on record, last reported at 19.88% in Q4 2025.

  • For Q4 2025, EBITDA Margin rose 1513.0% year-over-year to 19.88%; the TTM value through Dec 2025 reached 19.05%, up 1033.0%, while the annual FY2025 figure was 16.3%, 370.0% up from the prior year.
  • EBITDA Margin reached 19.88% in Q4 2025 per HAE's latest filing, up from 17.87% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 21.58% in Q1 2025 and bottomed at 9.41% in Q2 2021.
  • Average EBITDA Margin over 5 years is 9.58%, with a median of 9.17% recorded in 2022.
  • Peak YoY movement for EBITDA Margin: plummeted -2031bps in 2021, then skyrocketed 1665bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 6.01% in 2021, then soared by 104bps to 12.25% in 2022, then decreased by -4bps to 11.77% in 2023, then tumbled by -60bps to 4.75% in 2024, then skyrocketed by 319bps to 19.88% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 19.88% in Q4 2025, 17.87% in Q3 2025, and 16.76% in Q2 2025.